TY - JOUR
T1 - VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer.
JO - Journal of Clinical Oncology
PY - 2018/05/20
AU - Redchenko I
AU - Cappuccini F
AU - Pollock E
AU - Bryant RJ
AU - Carter L
AU - Verrill C
AU - Hollidge J
AU - Goodwin L
AU - Harrop R
AU - Romero PJ
AU - Vigano S et al
ED -
DO - DOI: 10.1200/jco.2018.36.15_suppl.3018
PB - American Society of Clinical Oncology (ASCO)
VL - 36
IS - 15_suppl
SP - 3018
EP - 3018
Y2 - 2025/07/27
ER -